Hemostasis Today

May, 2026
May 2026
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Ali Saad Al-shammari: Exploring the Role of SGLT2 Inhibitors After TAVI
May 16, 2026, 14:03

Ali Saad Al-shammari: Exploring the Role of SGLT2 Inhibitors After TAVI

Ali Saad Al-shammari, Physician and Cardiology Researcher, shared a post on LinkedIn about recent article by Khadeeja Ali Hamzah et al., published in European Journal of Clinical Pharmacology, adding:

“Proud to share that our systematic review and meta-analysis has been published in the European Journal of Clinical Pharmacology:

‘Therapeutic impact of SGLT2 inhibitors following transcatheter aortic valve implantation:

a GRADE-assessed systematic review and meta-analysis.’

We conducted a PRISMA-guided review of four studies including 12,374 TAVI patients, comparing SGLT2 inhibitors with standard care.

SGLT2 inhibitor therapy was associated with lower:

All-cause mortality: RR 0.62

HF hospitalization: RR 0.67

Myocardial infarction: RR 0.83

Bleeding events: RR 0.81

No significant differences were observed for cardiac death, stroke, pacemaker implantation, or AKI.

While these findings suggest a promising role for SGLT2 inhibitors after TAVI, the evidence remains limited and largely observational. Further randomized trials are needed.

Grateful to all co-authors khadeeja ali, Yousif Kurmasha, Mohammedsadeq A. Shweliya, Muhammad Shahzaib, Atef Akoum their collaboration.”

Title: Therapeutic impact of SGLT2 inhibitors following transcatheter aortic valve implantation: a grade-assessed systematic review and meta-analysis

Authors: Khadeeja Ali Hamzah, Yousif Hameed Kurmasha, Ali Saad Al-Shammari, Mohammedsadeq A Shweliya, Ali Alsajad Hussein Al-Janabi, Muhammad Shahzaib, Atef Akoum, Yasar Sattar

Ali Saad Al-shammari

Stay updated on all scientific advances with Hemostasis Today.